UB Paderborn / Katalog / Suche / in CDI

1 – 22 von 22

Sortiert nach

Preclinical Characterization of G1T28: A Novel CDK4/6 Inhibitor for Reduction of Chemotherapy-Induced Myelosuppression

Molecular cancer therapeutics, 2016-05, Vol.15 (5), p.783-793

2016

Volltextzugriff (PDF)

Preclinical development of G1T38: A novel, potent and selective inhibitor of cyclin dependent kinases 4/6 for use as an oral antineoplastic in patients with CDK4/6 sensitive tumors

Oncotarget, 2017-06, Vol.8 (26), p.42343-42358

2017

Volltextzugriff (PDF)

Oxidation of Oxazolines and Thiazolines to Oxazoles and Thiazoles. Application of the Kharasch−Sosnovsky Reaction

Journal of organic chemistry, 1996-11, Vol.61 (23), p.8207-8215

1996

Volltextzugriff (PDF)

Potent, Selective, and Orally Efficacious Antagonists of Melanin-Concentrating Hormone Receptor 1

Journal of medicinal chemistry, 2006-11, Vol.49 (24), p.7095-7107

2006

Volltextzugriff (PDF)

Ketoamide-Based Inhibitors of Cysteine Protease, Cathepsin K: P3 Modifications

Journal of medicinal chemistry, 2004-10, Vol.47 (21), p.5057-5068

2004

Volltextzugriff (PDF)

Design of cathepsin K inhibitors for osteoporosis

Current topics in medicinal chemistry, 2005-12, Vol.5 (16), p.1639

2005

Volltextzugriff (PDF)

N-Phenyl-4-pyrazolo[1,5-b]pyridazin-3-ylpyrimidin-2-amines as Potent and Selective Inhibitors of Glycogen Synthase Kinase 3 with Good Cellular Efficacy

Journal of medicinal chemistry, 2004-09, Vol.47 (19), p.4716-4730

2004

Volltextzugriff (PDF)

Anthranilimide based glycogen phosphorylase inhibitors for the treatment of type 2 diabetes. Part 3: X-ray crystallographic characterization, core and urea optimization and in vivo efficacy

Bioorganic & medicinal chemistry letters, 2009-02, Vol.19 (4), p.1177-1182

2009

Volltextzugriff (PDF)

The discovery and optimization of pyrimidinone-containing MCH R1 antagonists

Bioorganic & medicinal chemistry letters, 2006-09, Vol.16 (18), p.4723-4727

2006

Volltextzugriff (PDF)

Design of Potent, Selective, and Orally Bioavailable Inhibitors of Cysteine Protease Cathepsin K

Journal of medicinal chemistry, 2004-01, Vol.47 (3), p.588-599

2004

Volltextzugriff (PDF)

Anthranilimide-based glycogen phosphorylase inhibitors for the treatment of Type 2 diabetes: 2. Optimization of serine and threonine ether amino acid residues

Bioorganic & medicinal chemistry letters, 2009-02, Vol.19 (3), p.981-985

2009

Volltextzugriff (PDF)

Novel and potent cyclic cyanamide-based cathepsin K inhibitors

Bioorganic & medicinal chemistry letters, 2005-04, Vol.15 (7), p.1815-1819

2005

Volltextzugriff (PDF)

6-(4-Chlorophenyl)-3-substituted-thieno[3,2-d]pyrimidin-4(3H)-one-Based Melanin-Concentrating Hormone Receptor 1 Antagonist

Journal of medicinal chemistry, 2006-11, Vol.49 (24), p.7108-7118

2006

Volltextzugriff (PDF)

Potent and Selective Ketoamide-Based Inhibitors of Cysteine Protease, Cathepsin K

Journal of medicinal chemistry, 2004-10, Vol.47 (21), p.5049-5056

2004

Volltextzugriff (PDF)

Anthranilimide-based glycogen phosphorylase inhibitors for the treatment of type 2 diabetes: 1. Identification of 1-amino-1-cycloalkyl carboxylic acid headgroups

Bioorganic & medicinal chemistry letters, 2009-02, Vol.19 (3), p.976-980

2009

Volltextzugriff (PDF)

Acyclic, orally bioavailable ketone-based cathepsin K inhibitors

Bioorganic & medicinal chemistry letters, 2007, Vol.17 (1), p.22-27

2007

Volltextzugriff (PDF)

Orally bioavailable small molecule ketoamide-based inhibitors of cathepsin K

Bioorganic & medicinal chemistry letters, 2004-05, Vol.14 (10), p.2543-2546

2004

Volltextzugriff (PDF)

P2-P3 conformationally constrained ketoamide-based inhibitors of cathepsin K

Bioorganic & medicinal chemistry letters, 2005-08, Vol.15 (15), p.3540-3546

2005

Volltextzugriff (PDF)

P 2–P 3 conformationally constrained ketoamide-based inhibitors of cathepsin K

Bioorganic & medicinal chemistry letters, 2005-08, Vol.15 (15), p.3540-3546

2005

Volltextzugriff (PDF)

Novel and Potent Cyclic Cyanamide-Based Cathepsin K Inhibitors

ChemInform, 2005-07, Vol.36 (30), p.no-no

2005

Volltextzugriff (PDF)

Orally Bioavailable Small Molecule Ketoamide-Based Inhibitors of Cathepsin K

ChemInform, 2004-09, Vol.35 (39), p.no-no

2004

Volltextzugriff (PDF)

Epidemiology of rare diseases in Brazil: protocol of the Brazilian Rare Diseases Network (RARAS-BRDN)

Orphanet journal of rare diseases, 2022-02, Vol.17 (1), p.84-84, Article 84

2022

Volltextzugriff (PDF)

1 – 22 von 22

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(19)
Mit Volltextzugriff
(21)

Publikationsform

Artikel
(22)

Sprache

Englisch
(22)
Japanisch
(4)

Erscheinungsjahr

n.n

Thema

Science & Technology
(19)
Life Sciences & Biomedicine
(18)
Chemistry, Medicinal
(15)
Pharmacology & Pharmacy
(15)
Animals
(13)
Biological And Medical Sciences
(12)
Medical Sciences
(12)
Pharmacology. Drug Treatments
(12)
Structure-Activity Relationship
(12)
Humans
(10)
Cathepsin K
(9)
Chemistry
(9)
Chemistry, Organic
(9)
Physical Sciences
(9)
Cathepsins - Antagonists & Inhibitors
(8)
Rats
(7)
Bones, Joints And Connective Tissue. Antiinflammatory Agents
(6)
Crystallography, X-Ray
(6)
Inhibitory Concentration 50
(6)
Mice
(6)

15 weitere anzeigen...

Weniger anzeigen...

Kollektion

3 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Preclinical Characterization of G1T28: A Novel CDK4/6 Inhibitor for Reduction of Chemotherapy-Induced Myelosuppression

Preclinical development of G1T38: A novel, potent and selective inhibitor of cyclin dependent kinases 4/6 for use as an oral antineoplastic in patients with CDK4/6 sensitive tumors

Oxidation of Oxazolines and Thiazolines to Oxazoles and Thiazoles. Application of the Kharasch−Sosnovsky Reaction

Potent, Selective, and Orally Efficacious Antagonists of Melanin-Concentrating Hormone Receptor 1

Ketoamide-Based Inhibitors of Cysteine Protease, Cathepsin K: P3 Modifications

Design of cathepsin K inhibitors for osteoporosis

N-Phenyl-4-pyrazolo[1,5-b]pyridazin-3-ylpyrimidin-2-amines as Potent and Selective Inhibitors of Glycogen Synthase Kinase 3 with Good Cellular Efficacy

Anthranilimide based glycogen phosphorylase inhibitors for the treatment of type 2 diabetes. Part 3: X-ray crystallographic characterization, core and urea optimization and in vivo efficacy

The discovery and optimization of pyrimidinone-containing MCH R1 antagonists

Design of Potent, Selective, and Orally Bioavailable Inhibitors of Cysteine Protease Cathepsin K

Anthranilimide-based glycogen phosphorylase inhibitors for the treatment of Type 2 diabetes: 2. Optimization of serine and threonine ether amino acid residues

Novel and potent cyclic cyanamide-based cathepsin K inhibitors

6-(4-Chlorophenyl)-3-substituted-thieno[3,2-d]pyrimidin-4(3H)-one-Based Melanin-Concentrating Hormone Receptor 1 Antagonist

Potent and Selective Ketoamide-Based Inhibitors of Cysteine Protease, Cathepsin K

Anthranilimide-based glycogen phosphorylase inhibitors for the treatment of type 2 diabetes: 1. Identification of 1-amino-1-cycloalkyl carboxylic acid headgroups

Acyclic, orally bioavailable ketone-based cathepsin K inhibitors

Orally bioavailable small molecule ketoamide-based inhibitors of cathepsin K

P2-P3 conformationally constrained ketoamide-based inhibitors of cathepsin K

P 2–P 3 conformationally constrained ketoamide-based inhibitors of cathepsin K

Novel and Potent Cyclic Cyanamide-Based Cathepsin K Inhibitors

Orally Bioavailable Small Molecule Ketoamide-Based Inhibitors of Cathepsin K

Epidemiology of rare diseases in Brazil: protocol of the Brazilian Rare Diseases Network (RARAS-BRDN)

Suchergebnisse filtern